Prestige Consumer Healthcare/$PBH
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Prestige Consumer Healthcare
Prestige Consumer Healthcare is one of the largest pure-play over-the-counter healthcare providers. It has a diverse portfolio composed of leading brands in niche consumer health categories. Prestige's key brands include Clear Eyes (redness relief), Dramamine (motion sickness relief), Monistat (vaginal anti-fungal), and Summer's Eve (feminine hygiene), and many of its brands enjoy category leadership and recommendations from medical professionals. The firm mainly plays in North America where it generates roughly 85% of its total revenue, and the remaining sales come from Australia, New Zealand, and certain Asian markets.
Ticker
$PBH
Sector
Primary listing
NYSE
Employees
600
Headquarters
Website
PBH Metrics
BasicAdvanced
$3.1B
14.84
$4.26
0.44
-
Price and volume
Market cap
$3.1B
Beta
0.44
52-week high
$90.04
52-week low
$62.95
Average daily volume
611K
Financial strength
Current ratio
4.382
Quick ratio
2.808
Long term debt to equity
55.733
Total debt to equity
56.197
Interest coverage (TTM)
7.81%
Profitability
EBITDA (TTM)
378.666
Gross margin (TTM)
56.93%
Net profit margin (TTM)
19.02%
Operating margin (TTM)
31.15%
Effective tax rate (TTM)
25.93%
Revenue per employee (TTM)
$1,870,000
Management effectiveness
Return on assets (TTM)
6.47%
Return on equity (TTM)
12.05%
Valuation
Price to earnings (TTM)
14.844
Price to revenue (TTM)
2.8
Price to book
1.68
Price to tangible book (TTM)
-3.22
Price to free cash flow (TTM)
11.712
Free cash flow yield (TTM)
8.54%
Free cash flow per share (TTM)
5.401
Growth
Revenue change (TTM)
0.63%
Earnings per share change (TTM)
4.18%
3-year revenue growth (CAGR)
0.77%
10-year revenue growth (CAGR)
3.94%
3-year earnings per share growth (CAGR)
2.21%
10-year earnings per share growth (CAGR)
9.88%
What the Analysts think about PBH
Analyst ratings (Buy, Hold, Sell) for Prestige Consumer Healthcare stock.
Bulls say / Bears say
The deal to acquire Pillar5 Pharma brings sterile manufacturing in-house for Clear Eyes, removing key third-party supply obstacles and positioning PBH to expand production capacity in the second half of FY2026. (Reuters)
International OTC segment revenues increased 6.1% year-over-year in Q1 FY2026, demonstrating the company’s effective geographic diversification and giving it a hedge against North American supply disruptions. (Nasdaq)
While revenue declined 6.6%, Q1 diluted EPS rose 6% to $0.95, driven by strong margin gains and disciplined cost management across the business. (Reuters)
Q1 FY2026 revenues dropped 6.6% to $249.5 million, mainly due to ongoing Clear Eyes supply shortages, exposing the company's vulnerability to heavy reliance on a single product line. (Reuters)
The company revised its full-year fiscal 2026 revenue outlook downward to $1.100 billion–$1.115 billion from $1.140 billion–$1.155 billion, indicating slower growth prospects than previously expected. (Reuters)
At the end of Q1, PBH had net long-term debt of $992.7 million compared to $139.5 million in cash and equivalents, leaving it with net debt above $850 million, which could limit its financial flexibility. (SEC)
Data summarised monthly by Lightyear AI. Last updated on 1 Sept 2025.
PBH Financial Performance
Revenues and expenses
PBH Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Prestige Consumer Healthcare stock?
Prestige Consumer Healthcare (PBH) has a market cap of $3.1B as of September 15, 2025.
What is the P/E ratio for Prestige Consumer Healthcare stock?
The price to earnings (P/E) ratio for Prestige Consumer Healthcare (PBH) stock is 14.84 as of September 15, 2025.
Does Prestige Consumer Healthcare stock pay dividends?
No, Prestige Consumer Healthcare (PBH) stock does not pay dividends to its shareholders as of September 15, 2025.
When is the next Prestige Consumer Healthcare dividend payment date?
Prestige Consumer Healthcare (PBH) stock does not pay dividends to its shareholders.
What is the beta indicator for Prestige Consumer Healthcare?
Prestige Consumer Healthcare (PBH) has a beta rating of 0.44. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.